A Review of Glioblastoma and Other Primary Brain Malignancies

Alick P. Wang

DOI: https://doi.org/10.1001/jama.2023.8587

2023-07-12

Abstract:To the Editor The recent Review about primary brain malignancies in adults recommended that "patients receiving the equivalent of prednisone 20 mg daily for more than a month...should receive prophylaxis for Pneumocystis jirovecii pneumonia." In Table 1 in the article, the authors listed the 4 recommended P jirovecii pneumonia prophylaxis medications with their doses and highlighted sulfamethoxazole-trimethoprim as the "preferred" agent with the justification that it "reduces incidence of P jirovecii pneumonia in non-HIV immunocompromised individuals from 6.2% to 0.2%." Although they provided 1 corresponding citation, the reference is a 2014 Cochrane review that included only trials of leukemia, solid organ transplant, and autologous bone marrow transplant and included only 1 sentence that mentioned patients with brain tumors: "Patients receiving corticosteroids for primary or metastatic brain tumours may be at a higher risk warranting prophylaxis." There is an accompanying citation to a single center's experience of P jirovecii pneumonia among patients without AIDS from 1963 to 1992, which reported that some patients had solid tumors; brain tumors were not specifically studied, but the article stated: "An emerging group at risk were patients with a primary or secondary brain neoplasm." A reference was then provided to an earlier article by the same author that calculated a P jirovecii pneumonia incidence rate of 1.3% (8 of 595 patients with brain tumors developed P jirovecii pneumonia).